These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21825240)

  • 41. Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease.
    Brusa L; Versace V; Koch G; Iani C; Stanzione P; Bernardi G; Centonze D
    Clin Neurophysiol; 2006 Sep; 117(9):1917-21. PubMed ID: 16887383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Objective measurement of dyskinesia in Parkinson's disease using a force plate.
    Chung KA; Lobb BM; Nutt JG; McNames J; Horak F
    Mov Disord; 2010 Apr; 25(5):602-8. PubMed ID: 20213818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
    Yamada K; Goto S; Hamasaki T; Kuratsu JI
    Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 45. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    De Reuck J; De Weweire M; Van Maele G; Santens P
    J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of levodopa effects by internal pallidal stimulation.
    Krack P; Pollak P; Limousin P; Hoffmann D; Benazzouz A; Benabid AL
    Mov Disord; 1998 Jul; 13(4):648-52. PubMed ID: 9686769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The management approaches to dyskinesia vary from country to country.
    Woitalla D; Mueller T; Russ H; Hock K; Haeger DA
    Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA; McDermott MP; Messing S
    Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of aging to the severity of different motor signs in Parkinson disease.
    Levy G; Louis ED; Cote L; Perez M; Mejia-Santana H; Andrews H; Harris J; Waters C; Ford B; Frucht S; Fahn S; Marder K
    Arch Neurol; 2005 Mar; 62(3):467-72. PubMed ID: 15767513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
    Molchadski I; Korczyn AD; Cohen OS; Katzav A; Nitzan Z; Chapman J; Hassin-Baer S
    Acta Neurol Scand; 2011 Feb; 123(2):117-21. PubMed ID: 21108621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative motor assessment of dyskinesias in Parkinson's disease.
    Schaeffer E; Maetzler W; Liepelt-Scarfone I; Sass C; Reilmann R; Berg D
    J Neural Transm (Vienna); 2015 Sep; 122(9):1271-8. PubMed ID: 25712401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
    Hong JY; Sunwoo MK; Yoon JH; Kang SY; Sohn YH; Lee PH; Kim SH
    PLoS One; 2020; 15(8):e0237472. PubMed ID: 32817705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Grip force abnormalities in de novo Parkinson's disease.
    Fellows SJ; Noth J
    Mov Disord; 2004 May; 19(5):560-5. PubMed ID: 15133821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).
    Lewitt PA; Hauser RA; Lu M; Nicholas AP; Weiner W; Coppard N; Leinonen M; Savola JM
    Neurology; 2012 Jul; 79(2):163-9. PubMed ID: 22744665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.